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Flare-up of allergic rhinitis has been implicated in worsening neuropsychiatric symptoms such as hyperactivity and 
anxiety in the general population, mostly supported by epidemiological data. However, it is unknown how such 
respiratory allergy symptoms affect behavioral symptoms in patients with intellectual disability and limited expressive 
language. These patients may express more severe behavioral symptoms partly due to frustration and anxiety, being 
under-diagnosed and undertreated secondary to a lack of proper communication means. Herein, we present two 
cases of patients with severely limited expressive language, in whom we observed marked improvement in behav-
ioral symptoms and even cognitive activity following control of their symptoms of allergic rhinitis with the use of 
omalizmab, a humanized anti-IgE antibody. The presented cases indicate that clinicians need to be aware of profound 
effects of allergy rhinitis on neuropsychiatric symptoms in individuals with limited expressive language.
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Background
The prevalence of immunoglobulin E (IgE)-mediated 
allergic diseases such as allergic rhinitis (AR) and atopic 
asthma is steadily rising in developed countries. One out 
of 4–5 individuals now suffers from allergic diseases, and 
the improvement of environmental hygiene may be partly 
responsible for the increase in the prevalence of allergy 
[1]. In addition to the alarming increase of their preva-
lence, allergic diseases have also begun to be recognized 
as an aggravating factor for neuropsychiatric conditions 
such as anxiety, obsessive–compulsive disorders (OCD), 
and attention deficiency hyperactivity disorders (ADHD). 
In children diagnosed with AR, the prevalence of ADHD 
was higher (p  <  0.001) in a large population study 
(N =  226,550) [2]. In another population study, ADHD 
individuals (N = 4692) revealed an increased risk of AR 
compared to non-ADHD controls (N = 18,768) [3].
Given the high prevalence of allergic disease in the 
general population, individuals with limited expressive 
language (LEL) are also expected to suffer from allergic 
diseases at a similar rate to the one observed in general 
population. Allergy symptoms are expected to elicit 
aberrant behaviors partly through pain and discom-
fort in these individuals. For example, nasal congestion 
and sinus headache may lead to self-injurious behaviors 
(SIBs) such as head banging, hand-biting, and nose-
picking in individuals with LEL. Neuropsychiatric condi-
tions such as anxiety and OCD can also be aggravated by 
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allergic symptoms as described in the general population, 
which may further aggravate SIBs.
In general, treatment measures for allergic disease 
are safe and readily available. Thus, timely diagnosis 
and treatment for allergic diseases can be important for 
controlling behavioral and neuropsychiatric symptoms 
in individuals with LEL. Although diagnosis of allergic 
diseases is usually straight forward in typically develop-
ing children, patients with LEL may be far more diffi-
cult to diagnose and manage, due to the lack of effective 
speech and often aberrant behaviors. This may be espe-
cially true for children diagnosed with autism spectrum 
behaviors (ASD) who often exhibit challenging behav-
iors in clinical settings. It is our experience that in ASD 
children, worsening behavioral symptoms (typically 
hyperactivity and irritability) due to “flare-up” of aller-
gic rhinitis during allergy seasons are frequently attrib-
uted inappropriately to the autism itself. With current 
medical education, primary care physicians and special-
ists are not well equipped for caring for patients with 
LEL. As a result, patients with LEL can be at high risk 
of being over-treated with neuropsychiatric medications 
for their behavioral symptoms, without consideration of 
the effects of allergy symptoms on their neuropsychiatric 
symptoms. This may be even more problematic in LEL 
subjects with severe allergy not responding to the first 
line allergy medications.
Currently in the United States, the second line allergy 
treatment is subcutaneous allergen immunotherapy 
(IT). This treatment requires subcutaneous injections of 
purified allergens in a doctor’s office weekly for the first 
4–6  months, until reaching the maintenance doses of 
allergens, and then every 4  weeks thereafter. It may be 
difficult for LEL children with problematic behaviors to 
tolerate this time-consuming procedure. In addition, IT 
is not universally effective; individuals reactive to multi-
ple allergens (so called poly-reactors) are less responsive 
to IT than those who react to limited numbers of aller-
gens [4].
Another second line treatment option became avail-
able in the last decade in the form of humanized anti-IgE 
antibody (omalizmab) [5]. This murine monoclonal anti-
body inhibits binding of IgE to the IgE receptor expressed 
on effector cells (i.e., mast cells, basophils, eosinophils, 
and dentritic cells) and blocks allergen induced immune 
responses [5]. Its action is not allergen specific, and 
treatment is required every 2 or 4  weeks, depending 
on a patient’s total IgE level prior to treatment. Clinical 
benefits of omalizmab are manifested in a few weeks as 
opposed to IT, which takes several months to produce 
symptomatic relief. Thus omalizmab is likely to be bet-
ter tolerated in LEL individuals with problematic behav-
iors. However, there is a small risk of systemic reaction 
or anaphylaxis with both aeroallergen IT and omalizmab 
(0.1–0.2 %) [4, 5].
We present 2 cases of such individuals (one with ASD 
and the other with developmental delay, congenital deaf-
ness, and other multiple congenital anomalies). In these 
2 subjects, omalizmab treatment resulted in marked 
improvement not only in their naso-ocular symptoms, 
but also in the neuropsychiatric symptoms (especially 
difficult behaviors and cognitive activity), illustrating the 
profound effects of respiratory allergy in neuropsychiat-
ric symptoms in subjects with LEL.
Case presentation
Case #1
Eleven-year-old Caucasian male who was previously eval-
uated in the pediatric allergy/immunology (A/I) clinic at 
6 years of age for non-IgE mediated food allergy. He was 
one of triplets born following in  vitro fertilization, and 
suffered from feeding difficulties, failure to thrive (FTT), 
and persistent gastrointestinal (GI) symptoms. ASD was 
diagnosed at 20 months of age by a developmental pedia-
trician at a nationally known autism diagnostic center; 
behavioral intervention measures were implemented 
before 2  years of age. However, he responded poorly to 
the behavioral intervention measures. At that time, he 
was diagnosed with food protein induced enterocolitis 
syndrome (FPIES) and advised to avoid offending food 
(mainly soy and cow’s milk protein). His FTT and GI 
symptoms resolved gradually following dietary interven-
tions (soy-free, dairy-free diet). He also started to reveal 
slow but steady progress in his cognitive development.
However, after 8  years of age, his parents recognized 
marked exacerbation of his behavioral symptoms (anxi-
ety, self-scripting, SIBs, and OCD behaviors) in spring 
months when his aeroallergen symptoms flared up. His 
spring allergy flare-up resulted in chronic sinusitis every 
year. The first line allergy medications (steroid nasal 
inhalers, a leukotriene receptor antagonist, and topical 
ophthalmic solutions for ocular allergy) failed to control 
his naso-ocular symptoms. At 11  years of age, he pre-
sented in our clinic with marked exacerbation of behavio-
ral symptoms starting in spring. His parents also reported 
that school teachers diagnosed him having developmen-
tal regression with loss of once-acquired cognitive skills. 
At the time of secondary presentation, his cognitive skills 
were less than 1 percentile by an evaluation conducted 
at his school; his teachers thought that he was unable to 
comprehend a simple arithmetic question such as 1 + 1.
His parents were concerned with possible pediat-
ric acute-onset neuropsychiatric syndrome, secondary 
to his worsening OCD/anxiety, frequent temper tan-
trums, and SIBs (banging heads, biting hands). In fact, 
he was expelled from his school due to his problematic 
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behaviors. Prior to presenting in our clinic for the sec-
ond time, he had been evaluated by several neurologists 
for possible metabolic, genetic, and infectious diseases 
that could have been associated with drastic changes in 
his behavioral symptoms. Neurological workup includ-
ing imaging studies and EEG was unrevealing, ruling 
out organic, metabolic, genetic, or infectious etiology. 
The only notable clinical findings were seasonal allergy 
symptoms worsening in spring with complications of 
sinusitis every year. His aeroallergen reactivity was con-
firmed, with presence of allergen-specific IgE against 
tree pollens (maple, birch, oak, elm, walnut, cottonwood, 
and white ash) in the serum. He was also moderately 
reactive to grass and weed pollens. Because of his lack 
of responses to the first line allergy medications, omal-
izmab (300 mg every 4 weeks) was started at 12 years of 
age, one month prior to the start of spring allergy season, 
since omalizmab is approved for children ≥12 years old 
in the United States. Allergen IT was deferred because of 
his difficult behaviors and his reactivity to multiple pol-
len allergens, which makes it less likely that he would 
respond favorably to allergen IT.
Omalizmab effectively controlled his naso-ocular 
symptoms within 1–2 months. After starting omalizmab, 
behavioral symptoms were much less variable in spring/
summer months (Fig. 1). His parents also began to sus-
pect that he was more capable than the level at which 
he was initially evaluated at his school. Eventually, he 
became able to attend another school where he made 
rapid progress academically. He was found to be capable 
of 3-digit addition/subtraction, multiplication, fraction, 
and division 18  months after starting omalizmab treat-
ment. Omalizmab dose was then increased due to sub-
optimal control of allergy symptoms, which was likely 
associated with the onset of puberty and a subsequent 
growth spurt. His AR symptoms became better con-
trolled with an increased dose of omalizmab (300  mg 
every 2 weeks), which resulted in further improvement of 
his behavioral symptoms, resolution of SIB, and excellent 
academic achievement. He was also found to be talented 
in music with perfect pitch. Improvement of his behav-
ioral symptoms are noted in changes in ABC scores as 
shown below. Unfortunately, interruption of omalizmab 
treatment due to delay in insurance approval, following 
changes in his insurance coverage, resulted in worsen-
ing of his behavioral symptoms in 2015 at 16  years of 
age. This was again resolved after resuming omalizmab 
treatment.
Case #2
10-year-old male with mixed ethnicity (half Asian/half 
Caucasian) was previously evaluated in the Pediatric 
Allergy/Immunology Clinic for delayed type food allergy 
around 4–5 years of age. He was born with multiple con-
genital anomalies including bilateral neurosensory hear-
ing loss, agenesis of right kidney, and congenital heart 
disease (CHD) (pulmonary atresia, ventricular septal 
defect, and patent ductus arteriosus). He had successful 
surgical repair of his CHD in his infancy. He has global 
developmental delay and has continued to be non-verbal. 
His GI symptoms were resolved with dietary interven-
tion, but he continued to be followed up in our clinic 
secondary to asthma and seasonal allergy symptoms. 
His major allergens were tree pollens, with significantly 
elevated allergen-specific IgE against oak and birch pol-
lens (Class V and class VI). He was also reactive to mul-
tiple tree, weed, and grass pollens. His allergy symptoms 
were initially reasonably well controlled with the first 
line allergy medications including steroid nasal inhaler, 
olopatadine ophthalmic solution, and montelukast, a 
leukotriene receptor antagonist. Anti-histamines were 
also used as needed. However, after 10 years of age, his 
spring allergy symptoms became more significant, with 
new onset of facial tics/anxiety/OCD behaviors, worsen-
ing hyperactivity and less focusing, resulting in distur-
bance of his school performance. Since he had pending 
surgical correction of his CHD at 13–14  year of age, 
along with his reactivity to multiple pollens, and his dis-
ability, he was considered to be at high risk of allergen 
IT. We thus elected to place him on omalizmab treat-
ment at 12 years of age, since omalizmab is approved for 
children ≥12 years old in the United States. Despite his 
aberrant behaviors, he tolerated omalizmab remarkably 
well with almost complete resolution of AR symptoms 
within 1–2 months after starting omalizmab. In parallel 
to resolution of AR symptoms, facial tics, anxiety, and 
OCD behaviors resolved, and his behavioral symptoms 
returned to his baseline. He then started to adapt sign 
language, gaining better communication skills.







Change in ABC score aer omalizmab treatment 
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Fig. 1 Aberrant Behavior Checklist (ABC) subscale scores before and 
after the omalizmab treatment in the case #1
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Conclusions
This study presents 2 LEL cases of individuals suffering 
from severe aeroallergen allergy which required the sec-
ond line allergy treatment, omalizmab. Remarkable find-
ings in these 2 LEL cases are marked attenuation of their 
problematic neuropsychiatric symptoms and subsequent 
improvement in the cognitive development, once respira-
tory allergy symptoms were under control. These 2 LEL 
cases revealed that respiratory allergy can manifest pro-
found detrimental effects on neuropsychiatric symptoms 
and cognitive activities in LEL individuals, illustrating 
the importance of optimal control of respiratory allergy 
symptoms in LEL subjects.
As detailed in the background section, the aggravating 
effects of respiratory allergy on neuropsychiatric symp-
toms has been convincingly shown by multiple epidemio-
logical studies in the general population. This finding is 
also very likely to be applicable for individuals with LEL. 
Unfortunately, IgE-mediated allergic diseases tend to 
be under-diagnosed and/or under-treated in LEL sub-
jects, based on our clinical experience. This is partly due 
to their impaired communication skills, but also to the 
difficulty of recognizing an association between behav-
ioral symptoms and allergy exacerbation. The 2 cases 
presented illustrate a need for high index of suspicion of 
underlying treatable medical conditions when assessing 
marked changes in neuropsychiatric symptoms in indi-
viduals with LEL.
It is relatively easy to try the first line allergy medica-
tions for symptomatic relief for suspected allergy in LEL 
subjects with or without supporting laboratory results. 
However, if their responses are suboptimal, a question 
will arise whether it is necessary to proceed to the sec-
ond line allergy treatment because of the cost and time 
required for such procedures. In addition, the presence 
of problematic behaviors may raise doubt concerning 
how the subject will tolerate the proposed procedures. 
This was in fact our initial concern. However, sup-
porting laboratory data and well documented seasonal 
changes in problematic behaviors, made us proceed to 
the second line allergy treatment. The presented 2 cases 
revealed remarkably favorable responses, and illustrate 
the importance of optimal control of allergy symptoms in 
LEL patients in terms of behavioral symptoms, and even 
cognitive development. Clinicians should seek the sec-
ond line allergy treatment measures if there is sufficient 
clinical evidence that supports expected efficacy of such 
measures.
Consent
Parents of these 2 presented cases have given their con-
sent for the case reports to be published. The signed con-
sent form was obtained prior to the submission of this 
manuscript.
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